MRUS - Merus NV Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 90.00 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 34.55 StockBond Score: 0.00 Company Description Merus NV a clinicalstage immunooncology company engages in the discovery and development of bispecific antibody therapeutics in the Netherlands Its bispecific antibody candidate pipeline includes Zenocutuzumab MCLA128 which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer as well as in Phase 12 clinical trials for the treatment of solid tumors that harbor Neuregulin 1 The company is also developing MCLA158 which is in a phase I clinical trial for the treatment of solid tumors MCLA145 which is in phase 1 clinical trials for the treatment of solid tumors MCLA129 which is in phase 12 clinical trials for the treatment of patients with advanced nonsmall cell lung cancer and other solid tumors and ONO4685 that is Phase 1 clinical trial to treat relapsedrefractory T cell lymphoma In addition it has collaboration agreement with Betta Pharmaceuticals Co Ltd for the research and development of stage bispecific antibody candidates include MCLA129 and collaboration with Incyte Corporation for the development of MCLA145 The company was incorporated in 2003 and is headquartered in Utrecht the Netherlands